Susquehanna Fundamental Investments LLC Purchases New Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 3,809 shares of the medical instruments supplier's stock, valued at approximately $351,000.

Other large investors have also recently added to or reduced their stakes in the company. Copeland Capital Management LLC lifted its position in shares of LeMaitre Vascular by 0.7% in the 4th quarter. Copeland Capital Management LLC now owns 1,172,015 shares of the medical instruments supplier's stock worth $107,990,000 after buying an additional 8,623 shares during the last quarter. Congress Asset Management Co. boosted its stake in LeMaitre Vascular by 1.8% in the fourth quarter. Congress Asset Management Co. now owns 722,325 shares of the medical instruments supplier's stock valued at $66,555,000 after acquiring an additional 13,009 shares during the period. Geode Capital Management LLC grew its holdings in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Geode Capital Management LLC now owns 550,260 shares of the medical instruments supplier's stock valued at $50,711,000 after purchasing an additional 7,737 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of LeMaitre Vascular by 0.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 284,779 shares of the medical instruments supplier's stock valued at $26,240,000 after purchasing an additional 1,680 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of LeMaitre Vascular by 7.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 259,429 shares of the medical instruments supplier's stock worth $23,904,000 after purchasing an additional 16,886 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Five research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $98.14.

Insider Transactions at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at $456,915.68. This represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 10.79% of the company's stock.

LeMaitre Vascular Trading Down 0.6 %

NASDAQ:LMAT traded down $0.46 during mid-day trading on Wednesday, reaching $81.63. 209,048 shares of the stock were exchanged, compared to its average volume of 162,691. The business has a fifty day moving average price of $84.77 and a 200 day moving average price of $93.23. LeMaitre Vascular, Inc. has a 1-year low of $71.42 and a 1-year high of $109.58. The firm has a market capitalization of $1.84 billion, a PE ratio of 44.61, a PEG ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm's revenue for the quarter was up 12.0% on a year-over-year basis. During the same period last year, the firm earned $0.44 earnings per share. On average, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 29th. Investors of record on Thursday, May 15th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.98%. LeMaitre Vascular's dividend payout ratio is 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.